Earnings summaries and quarterly performance for Predictive Oncology.
Executive leadership at Predictive Oncology.
Board of directors at Predictive Oncology.
Research analysts covering Predictive Oncology.
Recent press releases and 8-K filings for POAI.
Predictive Oncology Regains Nasdaq Compliance
POAI
Delisting/Listing Issues
- Predictive Oncology Inc. (POAI) announced on December 2, 2025, that it regained compliance with Nasdaq's minimum stockholders' equity requirement, effective December 1, 2025.
- This compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders' equity of $2,500,000, ensures the company's shares will continue to trade on the Nasdaq Capital Market.
- The company will be subject to a mandatory panel monitor for one year from December 1, 2025, during which any future non-compliance with the equity requirement will result in a delist determination without further cure periods.
1 day ago
Predictive Oncology Launches Digital Asset Treasury Strategy and Reports Q3 2025 Financials
POAI
New Projects/Investments
Earnings
Accounting Changes
- Predictive Oncology initiated a new digital asset treasury strategy on September 29, 2025, focused on Aethir's ATH token to establish a strategic compute reserve and generate revenue from AI infrastructure.
- As of November 10, 2025, the company held approximately 5.7 billion ATH tokens with a market value of approximately $145.9 million, of which 3.74 billion tokens are locked until December 2028.
- For Q3 2025, Predictive Oncology reported revenue of $3.6 million and a net loss of $77.7 million, primarily due to a $74.4 million non-cash loss on remeasurement of a derivative liability related to the new digital asset strategy.
- The company's financial statements for Q3 2025 are considered not indicative of its underlying cash position or financial performance due to complex, transient accounting entries from a private placement that closed on October 7, 2025.
- Predictive Oncology aims to achieve a high single-digit yield on its ATH tokens for fiscal year 2026 by leveraging strategies including staking, GPU leasing, and token rotation.
Nov 17, 2025, 2:00 PM
Predictive Oncology announces Q3 2025 results and new digital asset strategy
POAI
Earnings
New Projects/Investments
Accounting Changes
- Predictive Oncology reported a net loss of $77.7 million for the third quarter of 2025, primarily due to a $74.4 million non-cash loss on the remeasurement of a derivative liability related to its new digital asset treasury strategy.
- The company launched a new digital asset treasury strategy on September 29, 2025, focused on Aethir's ATH token, aiming to create the world's first strategic compute reserve to address AI infrastructure needs and generate revenue.
- As of November 10, 2025, Predictive Oncology held approximately 5.7 billion ATH tokens with a market value of approximately $145.9 million.
- The strategy involves converting ATH tokens into graphic processing units (GPUs) via the Aethir network to generate cash flow through GPU leasing and staking, with a target of achieving a high single-digit yield on ATH tokens for fiscal year 2026.
- Revenue for Q3 2025 was $3.6 million, largely unchanged from the comparable period in 2024, and cash flow used for operations for the nine months ended September 30, 2025, decreased by 26% to $5.9 million compared to the prior year.
Nov 17, 2025, 2:00 PM
Predictive Oncology Reports Q3 2025 Financials and Details New Digital Asset Strategy
POAI
Earnings
New Projects/Investments
Accounting Changes
- Predictive Oncology reported a net loss of $77.7 million for Q3 2025, primarily due to a $74.4 million non-cash loss on the remeasurement of a derivative liability related to its new digital asset treasury strategy. Revenue for the quarter was $3.6 million, largely unchanged from the comparable period in 2024.
- The company launched a new digital asset treasury strategy on September 29, 2025, focused on Aethir's ATH token, aiming to create the world's first strategic compute reserve. This initiative is intended to be a new revenue-generating business line by converting ATH tokens into GPUs and then into revenue.
- As of November 10, 2025, Predictive Oncology held approximately 5.7 billion ATH tokens with a market value of approximately $145.9 million. The company targets a high single-digit yield on these tokens for fiscal year 2026 through various allocation models including staking, GPU leasing, and token rotation.
- The CFO noted that the financial statements as of September 30, 2025, are not indicative of the company's underlying cash position or financial performance due to complex and transient accounting entries related to the digital asset treasury strategy.
- Predictive Oncology anticipates converting ATH tokens into fiat revenue by renting GPUs on the Aethir network to serve enterprise clients, with a near-term pipeline of potential contracts ranging from $3 million to $120 million. The company also expects a near-term refreshed brand and stock ticker to reflect its expanded strategic focus on AI infrastructure.
Nov 17, 2025, 2:00 PM
Predictive Oncology Inc. Updates on Q3 2025 Financial Results and Digital Asset Strategy
POAI
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Predictive Oncology Inc. (POAI) provided an update on its Q3 2025 financial results and its new digital asset treasury strategy on November 17, 2025.
- The strategy involves focusing on the Aethir ecosystem and its native token (ATH), aiming to capitalize on the projected $2.8 trillion global AI infrastructure spending by 2029.
- As of November 10, 2025, the company holds 5.7 billion ATH tokens valued at $145.9 million, and has $44.5 million in net cash available to purchase additional ATH.
- Predictive Oncology's FY'26 goal is to achieve a high single-digit percentage return on digital assets by leveraging multiple strategies to generate revenue and cash flow.
Nov 17, 2025, 1:00 PM
Predictive Oncology Inc. Reports Q3 2025 Financial Results and Digital Asset Strategy Update
POAI
Earnings
New Projects/Investments
- Predictive Oncology Inc. reported a net loss of $(77.65) million for the third quarter ended September 30, 2025, compared to $(3.09) million for the same period in 2024, with basic and diluted loss per common share from continuing operations at $(107.24). This includes a $74.4 million loss on derivative instruments related to its digital asset treasury strategy.
- As of November 10, 2025, the company held approximately 5.70 billion ATH tokens, with a market value of approximately $152.8 million, as part of its new digital asset strategy focused on the Aethir network.
- The company's cash and cash equivalents from continuing operations were $181,667 as of September 30, 2025, a decrease from $611,822 as of December 31, 2024.
- Revenue for Q3 2025 was $3,618, largely unchanged from $3,907 in the comparable period of 2024.
Nov 14, 2025, 10:25 PM
Predictive Oncology Reports Q3 2025 Results and Digital Asset Strategy Update
POAI
Earnings
New Projects/Investments
- Predictive Oncology initiated a digital asset treasury strategy focused on ATH, the native utility token of the Aethir network, receiving approximately $50.8 million in cash proceeds and in-kind contributions of ATH with a notional value of approximately $292.7 million.
- As of November 10, 2025, the company held approximately 5.70 billion ATH with a market value of approximately $152.8 million.
- For the third quarter ended September 30, 2025, the company reported a basic and diluted loss per common share of $(107.24) and a net loss of $(77,651,843), which included a $74.4 million derivative liability related to the digital asset strategy.
- The company concluded Q3 2025 with $181,667 in cash and cash equivalents and a stockholders' deficit of $77.4 million.
Nov 14, 2025, 10:12 PM
Predictive Oncology Announces Board and Leadership Appointments for Digital Asset Strategy
POAI
Board Change
Management Change
New Projects/Investments
- Predictive Oncology Inc. (POAI) announced additions to its leadership team and Board of Directors to support its new digital asset treasury strategy focused on the Aethir (ATH) token.
- Shawn Matthews, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, was appointed to the Board of Directors.
- Thomas McLaughlin was named Chief Investment Officer, and Sara Turken, JD, was appointed General Counsel.
- The company's new strategy leverages its AI-driven drug discovery capabilities and a digital asset treasury focused on the Aethir (ATH) token to benefit from the growing need for global AI infrastructure.
Oct 14, 2025, 12:00 PM
Predictive Oncology Announces Closing of Private Placements to Fund Digital Asset Treasury Strategy
POAI
New Projects/Investments
- Predictive Oncology Inc. announced the closing of two private investment in public equity transactions (PIPEs) on October 7, 2025, raising approximately $343.5 million.
- This capital raise supports the Company's new digital asset treasury strategy, which will focus on accumulating ATH, the native utility token of the Aethir ecosystem.
- The $343.5 million in proceeds included approximately $50.8 million in cash from the Cash PIPE and approximately $173.3 million in discounted value (representing a notional value of $292.7 million) from in-kind contributions of locked and unlocked ATH in the Crypto PIPE.
- The Company intends to use the in-kind ATH contribution to fund its digital asset treasury strategy and the remaining net proceeds primarily for the acquisition of ATH in the open market, as well as for working capital and general corporate purposes.
- All share and price per share information in the announcement is presented on a post-split basis, following a one-for-fifteen (1-for-15) reverse stock split that became effective on September 30, 2025.
Oct 8, 2025, 4:05 PM
Predictive Oncology Inc. Announces Digital Asset Treasury Strategy and $200 Million PIPE
POAI
New Projects/Investments
Revenue Acceleration/Inflection
- Predictive Oncology Inc. (POAI) is initiating a digital asset treasury strategy to acquire and manage digital assets, primarily ATH, effective upon the closing of Private Placements.
- The company has secured a Private Investment in Public Equity (PIPE) totaling $200 million, comprising $100 million in cash and $100 million in-kind. The net cash proceeds from the PIPE will be primarily used to purchase ATH.
- The strategy involves Aethir, described as the #1 DePIN company by revenue, generating over $150 million in Annual Recurring Revenue (ARR) and demonstrating 96.4% quarter-over-quarter revenue growth in Q1 2025. Aethir operates the largest GPU network globally with over 430,000 GPU containers.
- The company acknowledges potential dilution of outstanding common stock from the issuance of securities and faces regulatory risks, including the possibility of being required to register as a money services business or if digital assets are classified as securities, which could lead to significant compliance costs or operational shutdowns.
Sep 29, 2025, 10:32 PM
Quarterly earnings call transcripts for Predictive Oncology.